Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04729283
Other study ID # RC21_0015
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 12, 2021
Est. completion date March 3, 2023

Study information

Verified date April 2021
Source Nantes University Hospital
Contact Emilie DUCHALAIS-DASSONNEVILLE, PH
Phone 33240084322
Email Emilie.DASSONNEVILLE@chu-nantes.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this present study is to compare functional results and quality of life after sigmoidectomy for diverticulitis and sigmoid cancer.


Description:

Rectal resection surgery can lead to numerous complications in term of gastrointestinal results with onset of fecal incontinence or in contrast constipation, and in term of genitourinary results with occurrence of dysuria, erectile dysfunction, or vaginal dryness. The low anterior resection syndrome is defined by the occurrence after rectal resection, of gastrointestinal symptoms like fecal incontinence or stool evacuation difficulties, which affect quality of life, despite conservation of anal sphincter. This syndrome is now well known and used in many countries. However, there is a lack of data concerning gastrointestinal functional results after sigmoid surgery whether it is for cancer or diverticulitis. Some studies highlighted symptoms persistence in many patients after sigmoidectomy. Lately, the LARS score was used after sigmoidectomy for cancer. This study reveals symptoms of low anterior resection syndrome for 41 % of patients. The correlation between rectal resection and sigmoidectomy could be explain by the resection of the upper part of rectum in case of sigmoidectomy. The issue of genito-urinary disorders after sigmoidectomy are poorly researched. Previous studies demonstrate a higher risk of erectile disorders after pelvic surgery and especially for cancer. Currently, there is a lack of data on functional results and quality of life for patients who are going into sigmoid surgery, whether for cancer or diverticulitis. The aim of this longitudinal study is to compare digestive functional outcome, genitourinary outcomes and quality of life in patients who undergo sigmoid resection for diverticulitis and cancer.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date March 3, 2023
Est. primary completion date March 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria : - Adults - Patients who undergo sigmoidectomy with end to end anastomosis for sigmoid cancer and symptomatic diverticulitis - Preservation of the left colic angle for upper surgical resection - Lower surgical resection located < 5cm to the recto-sigmoid junction Exclusion Criteria : - Minors - Adults under guardianship - Protected persons - Patients who undergo sigmoidectomy without anastomosis (ileostomy or Hartmann surgery) - Patients who undergo surgery in emergency - Cancer of recto-sigmoid junction - Patients who undergo secondarily a stoma

Study Design


Intervention

Procedure:
Sigmoidectomy
The sigmoid resection surgery, realized by laparoscopy or laparotomy, with anastomosis.

Locations

Country Name City State
France Angers University Hospital Angers Maine-et-Loire
France Caen University Hospital Caen Calvados
France Vendée Departmental Hospital La Roche-sur-Yon Vendée
France Nantes University Hospital Nantes Loire-Atlantique

Sponsors (1)

Lead Sponsor Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary LARS score To measure incontinence troubles after low anterior resection. The score is from 0 to 42. The higher the score, the worst the incontinence. At the visit of preoperative
Primary LARS score To measure incontinence troubles after low anterior resection. The score is from 0 to 42. The higher the score, the worst the incontinence. At the visit of one month
Primary LARS score To measure incontinence troubles after low anterior resection. The score is from 0 to 42. The higher the score, the worst the incontinence. At the visit of three months
Primary LARS score To measure incontinence troubles after low anterior resection. The score is from 0 to 42. The higher the score, the worst the incontinence. At the visit of six months
Primary LARS score To measure incontinence troubles after low anterior resection. The score is from 0 to 42. The higher the score, the worst the incontinence. At the visit of twelve months
Secondary Bristol stool chart A scale to classify the form of the stools in seven category which indicate constipation or diarrhea in function of the type.
Types 1 and 2 indicate constipation, types 3 and 4 are normal stools, type 5, 6 and 7 indicate diarrhea.
At the visit of preoperative
Secondary Bristol stool chart A scale to classify the form of the stools in seven category which indicate constipation or diarrhea in function of the type.
Types 1 and 2 indicate constipation, types 3 and 4 are normal stools, type 5, 6 and 7 indicate diarrhea.
At the visit of one month
Secondary Bristol stool chart A scale to classify the form of the stools in seven category which indicate constipation or diarrhea in function of the type.
Types 1 and 2 indicate constipation, types 3 and 4 are normal stools, type 5, 6 and 7 indicate diarrhea.
At the visit of three months
Secondary Bristol stool chart A scale to classify the form of the stools in seven category which indicate constipation or diarrhea in function of the type.
Types 1 and 2 indicate constipation, types 3 and 4 are normal stools, type 5, 6 and 7 indicate diarrhea.
At the visit of six months
Secondary Bristol stool chart A scale to classify the form of the stools in seven category which indicate constipation or diarrhea in function of the type.
Types 1 and 2 indicate constipation, types 3 and 4 are normal stools, type 5, 6 and 7 indicate diarrhea.
At the visit of twelve months
Secondary GIQLI Quality of life related to gastrointestinal symptoms. Score from 0 to 144. The higher the score, the better the quality of life. At the visit of preoperative
Secondary GIQLI Quality of life related to gastrointestinal symptoms. Score from 0 to 144. The higher the score, the better the quality of life. At the visit of one month
Secondary GIQLI Quality of life related to gastrointestinal symptoms. Score from 0 to 144. The higher the score, the better the quality of life. At the visit of three months
Secondary GIQLI Quality of life related to gastrointestinal symptoms. Score from 0 to 144. The higher the score, the better the quality of life. At the visit of six months
Secondary GIQLI Quality of life related to gastrointestinal symptoms. Score from 0 to 144. The higher the score, the better the quality of life. At the visit of twelve months
Secondary SF-36 General quality of life score. Described with 8 scaled scores, which are : vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, social role functioning, mental health.
Each scale score is from 0 to 100. The higher the score the less disability.
At the visit of preoperative
Secondary SF-36 General quality of life score. Described with 8 scaled scores, which are : vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, social role functioning, mental health.
Each scale score is from 0 to 100. The higher the score the less disability.
At the visit of one month
Secondary SF-36 General quality of life score. Described with 8 scaled scores, which are : vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, social role functioning, mental health.
Each scale score is from 0 to 100. The higher the score the less disability.
At the visit of three months
Secondary SF-36 General quality of life score. Described with 8 scaled scores, which are : vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, social role functioning, mental health.
Each scale score is from 0 to 100. The higher the score the less disability.
At the visit of six months
Secondary SF-36 General quality of life score. Described with 8 scaled scores, which are : vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, social role functioning, mental health.
Each scale score is from 0 to 100. The higher the score the less disability.
At the visit of twelve months
Secondary FSFI Measure of sexual functioning in women. Score from 0 to 95. The higher the score, the better the sexual function. At the visit of preoperative
Secondary FSFI Measure of sexual functioning in women. Score from 0 to 95. The higher the score, the better the sexual function. At the visit of one month
Secondary FSFI Measure of sexual functioning in women. Score from 0 to 95. The higher the score, the better the sexual function. At the visit of three months
Secondary FSFI Measure of sexual functioning in women. Score from 0 to 95. The higher the score, the better the sexual function. At the visit of six months
Secondary FSFI Measure of sexual functioning in women. Score from 0 to 95. The higher the score, the better the sexual function. At the visit of twelve months
Secondary ICIQ-FLUTS Questionary for evaluating female lower urinary tract symptoms and impact on quality of life.
Score from 0 to 48. The higher the score, the worst the urinary continence.
At the visit of preoperative
Secondary ICIQ-FLUTS Questionary for evaluating female lower urinary tract symptoms and impact on quality of life.
Score from 0 to 48. The higher the score, the worst the urinary continence.
At the visit of one month
Secondary ICIQ-FLUTS Questionary for evaluating female lower urinary tract symptoms and impact on quality of life.
Score from 0 to 48. The higher the score, the worst the urinary continence.
At the visit of three months
Secondary ICIQ-FLUTS Questionary for evaluating female lower urinary tract symptoms and impact on quality of life.
Score from 0 to 48. The higher the score, the worst the urinary continence.
At the visit of six months
Secondary ICIQ-FLUTS Questionary for evaluating female lower urinary tract symptoms and impact on quality of life.
Score from 0 to 48. The higher the score, the worst the urinary continence.
At the visit of twelve months
Secondary IPSS Questionary to screen and manage symptoms of benign prostatic hyperplasia. Score from 0 to 35. The higher the score, the worst the urinary function. At the visit of preoperative
Secondary IPSS Questionary to screen and manage symptoms of benign prostatic hyperplasia. Score from 0 to 35. The higher the score, the worst the urinary function. At the visit of one month
Secondary IPSS Questionary to screen and manage symptoms of benign prostatic hyperplasia. Score from 0 to 35. The higher the score, the worst the urinary function. At the visit of three months
Secondary IPSS Questionary to screen and manage symptoms of benign prostatic hyperplasia. Score from 0 to 35. The higher the score, the worst the urinary function. At the visit of six months
Secondary IPSS Questionary to screen and manage symptoms of benign prostatic hyperplasia. Score from 0 to 35. The higher the score, the worst the urinary function. At the visit of twelve months
Secondary IIEF5 Questionary about erection problems on patient's sex life. Score from 1 to 25. The higher the score, the better the sexual function. At the visit of preoperative
Secondary IIEF5 Questionary about erection problems on patient's sex life. Score from 1 to 25. The higher the score, the better the sexual function. At the visit of one month
Secondary IIEF5 Questionary about erection problems on patient's sex life. Score from 1 to 25. The higher the score, the better the sexual function. At the visit of three months
Secondary IIEF5 Questionary about erection problems on patient's sex life. Score from 1 to 25. The higher the score, the better the sexual function. At the visit of six months
Secondary IIEF5 Questionary about erection problems on patient's sex life. Score from 1 to 25. The higher the score, the better the sexual function. At the visit of twelve months
See also
  Status Clinical Trial Phase
Completed NCT03083951 - Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL) N/A
Completed NCT03390517 - A Study of Perfusion of Colorectal Anastomosis Using FLuorescence AnGiography (FLAG-trial) N/A
Not yet recruiting NCT06396806 - A Prospective, Randomized, Open, Parallel-controlled, Superior-efficacy Clinical Study of Radical Sigmoidectomy for Sigmoid Cancer Versus Radical Sigmoidectomy Combined With Indocyanine Green Fluorescence Imaging Lymphatic Tracing Dissection in the Treatment of Sigmoid Cancer N/A
Completed NCT04744792 - QoL of Colorectal Cancer Patients and Spouses
Completed NCT03259828 - Sigmoid Colon Organ Motion in Radiotherapy N/A